维立志博累亏超7亿:百济神州今年终止协议,短期偿债压力偏大

港湾商业观察
Jun 19, 2025

《港湾商业观察》施子夫近日,南京维立志博生物科技股份有限公司(以下简称,维立志博)再度向港交所递交招股书冲刺上市,联席保荐人为摩根士丹利和中信证券。2024年11月末,维立志博首度递表港交所,其后失效未果。二度冲刺之下,公司的经营情况仍不容乐观。1无商业化持续亏损超7亿,百济神州终止协议招股书及天眼查显示,维立志博成立于2012年,是一家临床阶段生物科技公司,专注于中国及全球肿瘤、自身免疫性疾病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10